HomeCompareCMRAW vs QYLD

CMRAW vs QYLD: Dividend Comparison 2026

CMRAW yields 10362.69% · QYLD yields 12.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMRAW wins by $78335784849600944.00M in total portfolio value
10 years
CMRAW
CMRAW
● Live price
10362.69%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78335784849600944.00M
Annual income
$76,876,438,600,915,240,000,000.00
Full CMRAW calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
12.24%
Share price
$16.70
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$6,038.84
Full QYLD calculator →

Portfolio growth — CMRAW vs QYLD

📍 CMRAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMRAWQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMRAW + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMRAW pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMRAW
Annual income on $10K today (after 15% tax)
$880,829.02/yr
After 10yr DRIP, annual income (after tax)
$65,344,972,810,777,950,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,040.82/yr
After 10yr DRIP, annual income (after tax)
$5,133.01/yr
At 15% tax rate, CMRAW beats the other by $65,344,972,810,777,950,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMRAW + QYLD for your $10,000?

CMRAW: 50%QYLD: 50%
100% QYLD50/50100% CMRAW
Portfolio after 10yr
$39167892424800472.00M
Annual income
$38,438,219,300,457,620,000,000.00/yr
Blended yield
98.14%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMRAW buys
0
QYLD buys
0
No recent congressional trades found for CMRAW or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMRAWQYLD
Forward yield10362.69%12.24%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$78335784849600944.00M$26.5K
Annual income after 10y$76,876,438,600,915,240,000,000.00$6,038.84
Total dividends collected$78238734181699024.00M$28.5K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CMRAW vs QYLD ($10,000, DRIP)

YearCMRAW PortfolioCMRAW Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$1,046,969$1,036,269.43$10,384$1,224.49+$1.04MCMRAW
2$102,516,745$101,396,487.34$10,900$1,388.18+$102.51MCMRAW
3$9,388,666,498$9,278,973,581.18$11,576$1,590.76+$9388.65MCMRAW
4$804,237,430,573$794,191,557,419.90$12,447$1,844.20+$804237.42MCMRAW
5$64,440,729,401,315$63,580,195,350,601.93$13,567$2,164.97+$64440729.39MCMRAW
6$4,830,127,690,198,710$4,761,176,109,739,303.00$15,003$2,576.05+$4830127690.18MCMRAW
7$338,693,420,711,903,550$333,525,184,083,391,000.00$16,853$3,110.04+$338693420711.89MCMRAW
8$22,219,525,310,042,270,000$21,857,123,349,880,533,000.00$19,251$3,813.85+$22219525310042.25MCMRAW
9$1,363,874,998,771,683,700,000$1,340,100,106,689,938,500,000.00$22,390$4,756.08+$1363874998771683.75MCMRAW
10$78,335,784,849,600,940,000,000$76,876,438,600,915,240,000,000.00$26,548$6,038.84+$78335784849600944.00MCMRAW

CMRAW vs QYLD: Complete Analysis 2026

CMRAWStock

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Full CMRAW Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this CMRAW vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMRAW vs SCHDCMRAW vs JEPICMRAW vs OCMRAW vs KOCMRAW vs MAINCMRAW vs XYLDCMRAW vs JEPQCMRAW vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.